World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
29483
World Ranking
17864
National Ranking
1624

Anthony H. Goldstone publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Anthony H. Goldstone sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 239 publications — 7th percentile

7% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Anthony H. Goldstone D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Anthony H. Goldstone sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Anthony H. Goldstone is affiliated with University College Hospital in the United Kingdom. Their research spans multiple areas within medicine, particularly focusing on the intersections of physiology, genetics, endocrinology, and metabolism.

The primary fields of study for Goldstone include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader categories, their work engages significantly with subfields such as:

  • Physiology
  • Genetics
  • Surgery
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems

The main research topics Goldstone addresses are diverse and include:

  • Diet and metabolism studies
  • Genetic Syndromes and Imprinting
  • Bariatric Surgery and Outcomes
  • Regulation of Appetite and Obesity
  • Genetics and Neurodevelopmental Disorders
  • Adipose Tissue and Metabolism
  • Eating Disorders and Behaviors

Frequent publication venues for Goldstone's work feature journals such as:

  • Journal of the Endocrine Society
  • The Journal of Clinical Endocrinology & Metabolism
  • Journal of Clinical Medicine
  • Appetite
  • Obesity

Among Goldstone's recent scholarly contributions are the following papers:

  • The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: a review (2021, Progress in Neuro-Psychopharmacology and Biological Psychiatry)
  • Central Adrenal Insufficiency Is Rare in Adults With Prader-Willi Syndrome (2020, The Journal of Clinical Endocrinology & Metabolism)
  • Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial (2023, The Journal of Clinical Endocrinology & Metabolism)
  • Duodenal-Jejunal Bypass Liner for the management of Type 2 Diabetes Mellitus and Obesity (2021, Annals of Surgery)
  • Role of the ghrelin system in alcohol use disorder and alcohol-associated liver disease: A narrative review (2022, Alcoholism Clinical and Experimental Research)

Goldstone collaborates regularly with a selected group of co-authors including:

  • Alexander D. Miras
  • Christina Prechtl
  • Aruchuna Ruban
  • Michael A. Glaysher
  • James Byrne

Best Publications

  • The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

    David Grimwade;Helen Walker;Fiona Oliver;Keith Wheatley

  • The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

    Panagiotis D. Kottaridis;Rosemary E. Gale;Marion E. Frew;Georgina Harrison

  • Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

    David Grimwade;Robert K. Hills;Anthony V. Moorman;Helen Walker

  • Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

    Norbert Schmitz;Beate Pfistner;Michael Sextro;Markus Sieber

  • In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

    Anthony H. Goldstone;Susan M. Richards;Hilliard M. Lazarus;Martin S. Tallman

  • The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

    David Grimwade;Helen Walker;Georgina Harrison;Fiona Oliver

  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

    T. Philip;James Olen Armitage;G. Spitzer;F. Chauvin

  • Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

    Adele K. Fielding;Susan M. Richards;Rajesh Chopra;Hillard M. Lazarus

  • Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial

    Alan Kenneth Burnett;Anthony H. Goldstone;Richard M. F. Stevens;Ian M. Hann

  • A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment†‡

    Alan Kenneth Burnett;Donald Milligan;Archie G. Prentice;Anthony H. Goldstone

  • Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993

    Jacob M. Rowe;Georgina Buck;Alan Kenneth Burnett;Raj Chopra

  • Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

    N Schmitz;P Dreger;D.C Linch;A.H Goldstone

  • Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

    Alan Kenneth Burnett;Robert Kerrin Hills;Donald Milligan;Lars Kjeldsen

  • Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

    Anthony V. Moorman;Christine J. Harrison;Georgina A.N. Buck;Sue M. Richards

  • A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties.

    Keith Wheatley;Alan Kenneth Burnett;Anthony H. Goldstone;Richard G. Gray

  • Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.

    Anthony H. Goldstone;Alan Kenneth Burnett;Keith Wheatley;Alastair G. Smith

  • In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

    Panagiotis D Kottaridis;Donald W Milligan;Rajesh Chopra;Ronjon Chakraverty

  • Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid: Result of the Randomized MRC Trial

    Alan K. Burnett;David Grimwade;Ellen Solomon;Keith Wheatley

  • ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

    JM Rowe;G Buck;AK Burnett;R Chopra

  • Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia

    A Moorman;C J Harrison;Buck Gan.;S M Richards

Frequent Co-Authors

David C. Linch
David C. Linch University College London
Alan Kenneth Burnett
Alan Kenneth Burnett University of Glasgow
Donald Milligan
Donald Milligan University of Birmingham
Karl S. Peggs
Karl S. Peggs University College London
Jacob M. Rowe
Jacob M. Rowe Technion – Israel Institute of Technology
Keith Wheatley
Keith Wheatley University of Birmingham
Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Mark R. Litzow
Mark R. Litzow Mayo Clinic
Robert Kerrin Hills
Robert Kerrin Hills University of Oxford
Emma Morris
Emma Morris University College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering alternative or supplementary pathways to a traditional medical degree, there are several online healthcare programs to explore. Careers in healthcare administration, pharmacy, and advanced nursing offer rewarding options with growing demand across the U.S.

If you are interested in management and leadership roles in healthcare, an online master of health administration program can equip you with essential skills in policy, finance, and organizational leadership. Many students are concerned about cost, so exploring the cheapest mha programs online healthcare is a smart strategy to find high-quality and affordable options.

For nursing professionals seeking advanced practice or leadership opportunities, the best online bsn to dnp programs offer flexible learning for career advancement. Similarly, pharmacy careers can begin with online education as well, and understanding online pharmacy school cost is important for making informed decisions about your investment in education.

These related degrees provide alternative routes into the healthcare sector, combining flexibility, affordability, and strong career prospects.

Best Scientists Citing Anthony H. Goldstone

Trending Scientists

Recently Published Articles